Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells - PubMed (original) (raw)
Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells
Naoko Imai et al. Eur J Immunol. 2009 Jan.
Free article
Abstract
It is becoming increasingly evident that the multifunctionality of effector cells at the single-cell level is an important factor to predict the quality of T-cell response in immunological protection. The significance of the multifunctionality of T cells in anti-tumor immunity, however, remains unclear. Here, we assessed the IFN-gamma and TNF-alpha production and CD107a mobilization in adoptively transferred tumor-antigen-specific CD8(+) T cells at the single-cell level. Tumor growth of the murine fibrosarcoma CMS5 was found to limit the induction of multifunctionality in the transferred cells. These cells exhibited insufficient acquisition of the CD25(high)GITR(high)CD62L(low) phenotype and reduced infiltration in tumor. Depletion of Treg facilitated the induction of high multifunctionality of the transferred cells even in the hosts with progressing tumor, leading to enhanced tumor regression. The multifunctionality of the transferred cells correlated with in vivo CTL activity, and T cells with high multifunctionality harvested from hosts with successful therapy induced tumor regression when re-transferred into the tumor-bearing hosts. These data suggest that the appearance of multifunctional CD8(+) effector T cells in vivo is a critical determinant of the success of anti-tumor immunotherapy and Treg play an important role in the mechanism inhibiting the induction of multifunctionality in effector cells.
Similar articles
- Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression.
Imai N, Ikeda H, Tawara I, Wang L, Wang L, Nishikawa H, Kato T, Shiku H. Imai N, et al. Cancer Sci. 2009 Jul;100(7):1317-25. doi: 10.1111/j.1349-7006.2009.01179.x. Epub 2009 Apr 29. Cancer Sci. 2009. PMID: 19432889 Free PMC article. - Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo.
Perret R, Ronchese F. Perret R, et al. Eur J Immunol. 2008 Oct;38(10):2886-95. doi: 10.1002/eji.200838483. Eur J Immunol. 2008. PMID: 18825745 - Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells.
Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y, Yamane M, Ueno H, Ideno M, Nukaya I, Enoki T, Mineno J, Takesako K, Hirano S, Shiku H. Hosoi H, et al. Eur J Immunol. 2014 Jun;44(6):1747-58. doi: 10.1002/eji.201343969. Epub 2014 May 11. Eur J Immunol. 2014. PMID: 24723437 - A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes.
Maxeiner JH, Karwot R, Sauer K, Scholtes P, Boross I, Koslowski M, Türeci O, Wiewrodt R, Neurath MF, Lehr HA, Finotto S. Maxeiner JH, et al. Cancer Res. 2009 Apr 1;69(7):3069-76. doi: 10.1158/0008-5472.CAN-08-1678. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318584 - Tumor escape mechanism governed by myeloid-derived suppressor cells.
Nagaraj S, Gabrilovich DI. Nagaraj S, et al. Cancer Res. 2008 Apr 15;68(8):2561-3. doi: 10.1158/0008-5472.CAN-07-6229. Cancer Res. 2008. PMID: 18413722 Review.
Cited by
- Development of TCR-T cell therapy targeting mismatched HLA-DPB1 for relapsed leukemia after allogeneic transplantation.
Barakat C, Inagaki Y, Mizuno S, Nishio N, Katsuyama N, Sato Y, Kobayashi M, Ozeki K, Iida H, Tomita A, Sawa M, Demachi-Okamura A, Takahashi Y, Nishikawa H, Akatsuka Y. Barakat C, et al. Int J Hematol. 2023 Aug;118(2):252-266. doi: 10.1007/s12185-023-03621-y. Epub 2023 Jun 13. Int J Hematol. 2023. PMID: 37310580 - Activated T cell therapy targeting glioblastoma cancer stem cells.
Miyaguchi K, Wang H, Black KL, Shiao SL, Wang R, Yu JS. Miyaguchi K, et al. Sci Rep. 2023 Jan 5;13(1):196. doi: 10.1038/s41598-022-27184-w. Sci Rep. 2023. PMID: 36604465 Free PMC article. - Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4- T Cells.
Liu Q, Wang L, Lin H, Wang Z, Wu J, Guo J, Wen S, Ran L, Yue Z, Su X, Wu Q, Tang J, Li Z, Hu L, Xu L, Ye L, Huang Q. Liu Q, et al. Front Immunol. 2022 Jun 16;13:875718. doi: 10.3389/fimmu.2022.875718. eCollection 2022. Front Immunol. 2022. PMID: 35784297 Free PMC article. - Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement.
Chin AL, Jiang S, Jang E, Niu L, Li L, Jia X, Tong R. Chin AL, et al. Nat Commun. 2021 Aug 26;12(1):5138. doi: 10.1038/s41467-021-25391-z. Nat Commun. 2021. PMID: 34446702 Free PMC article. - Infiltrating Immune Cells in Gastric Cancer: A Novel Predicting Model for Prognosis.
Li W, Li M, Wang H, Peng Y, Dong S, Lu Y, Wang F, Xu F, Liu L, Zhao Q. Li W, et al. J Cancer. 2021 Jan 1;12(4):965-975. doi: 10.7150/jca.51079. eCollection 2021. J Cancer. 2021. PMID: 33442396 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials